Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer

Abstract Methylation alterations of specific genes have recently been identified as diagnostic biomarkers for human cancers. Although MEG3 has been proved to be a tumor suppressor in cervical cancer according to our previous study, the diagnostic value of MEG3 methylation in plasma is still unknown....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jun Zhang, Tingting Yao, Zhongqiu Lin, Yali Gao
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/78870cd80ff04119a01a8e50d2580630
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:78870cd80ff04119a01a8e50d2580630
record_format	dspace
spelling	oai:doaj.org-article:78870cd80ff04119a01a8e50d25806302021-12-02T11:53:05ZAberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer10.1038/s41598-017-06502-72045-2322https://doaj.org/article/78870cd80ff04119a01a8e50d25806302017-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-06502-7https://doaj.org/toc/2045-2322Abstract Methylation alterations of specific genes have recently been identified as diagnostic biomarkers for human cancers. Although MEG3 has been proved to be a tumor suppressor in cervical cancer according to our previous study, the diagnostic value of MEG3 methylation in plasma is still unknown. Therefore, the aim of this study is to identify a novel epigenetic biomarker for cervical cancer. In the current study, the level of MEG3 methylation was evaluated using methylation-specific polymerase chain reaction. The results showed that the level of MEG3 methylation was significantly higher in cervical cancer tissues and patients’ plasmas than those in adjacent normal tissues and plasmas of healthy participants respectively. Moreover, the accuracy was good enough for MEG3 methylation in plasma to discriminate CIN III patients from healthy participants. In addition, MEG3 methylation in plasma also has high discriminating power to predict HR-HPV infection and lymph node metastasis. Furthermore, hypermethylation of MEG3 in plasma was associated with worse recurrence-free and overall survival in cervical cancer patients. In conclusions, MEG3 methylation in plasma can serve as a diagnostic and prognostic biomarker for cervical cancer, providing useful information for clinical management.Jun ZhangTingting YaoZhongqiu LinYali GaoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jun Zhang Tingting Yao Zhongqiu Lin Yali Gao Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
description	Abstract Methylation alterations of specific genes have recently been identified as diagnostic biomarkers for human cancers. Although MEG3 has been proved to be a tumor suppressor in cervical cancer according to our previous study, the diagnostic value of MEG3 methylation in plasma is still unknown. Therefore, the aim of this study is to identify a novel epigenetic biomarker for cervical cancer. In the current study, the level of MEG3 methylation was evaluated using methylation-specific polymerase chain reaction. The results showed that the level of MEG3 methylation was significantly higher in cervical cancer tissues and patients’ plasmas than those in adjacent normal tissues and plasmas of healthy participants respectively. Moreover, the accuracy was good enough for MEG3 methylation in plasma to discriminate CIN III patients from healthy participants. In addition, MEG3 methylation in plasma also has high discriminating power to predict HR-HPV infection and lymph node metastasis. Furthermore, hypermethylation of MEG3 in plasma was associated with worse recurrence-free and overall survival in cervical cancer patients. In conclusions, MEG3 methylation in plasma can serve as a diagnostic and prognostic biomarker for cervical cancer, providing useful information for clinical management.
format	article
author	Jun Zhang Tingting Yao Zhongqiu Lin Yali Gao
author_facet	Jun Zhang Tingting Yao Zhongqiu Lin Yali Gao
author_sort	Jun Zhang
title	Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
title_short	Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
title_full	Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
title_fullStr	Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
title_full_unstemmed	Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
title_sort	aberrant methylation of meg3 functions as a potential plasma-based biomarker for cervical cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/78870cd80ff04119a01a8e50d2580630
work_keys_str_mv	AT junzhang aberrantmethylationofmeg3functionsasapotentialplasmabasedbiomarkerforcervicalcancer AT tingtingyao aberrantmethylationofmeg3functionsasapotentialplasmabasedbiomarkerforcervicalcancer AT zhongqiulin aberrantmethylationofmeg3functionsasapotentialplasmabasedbiomarkerforcervicalcancer AT yaligao aberrantmethylationofmeg3functionsasapotentialplasmabasedbiomarkerforcervicalcancer
_version_	1718394873334202368

Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer

Ejemplares similares